– Reuters
EF Hutton Maintains Buy on Jasper Therapeutics, Maintains $4 Price Target
EF Hutton analyst Michael King maintains Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $4 price target.
Related Posts
Why These Uber Analysts Are Bullish Ahead Of Q4 Earnings
Uber Technologies Inc. (NYSE: UBER) will issue its fourth-quarter 2022 earnings on Feb. 8 before market open, here’s what the Street is expecting.
Zoned Properties FY22 Revenue Grows 46% To $2.66M, Sixth Year Of Positive Cash Flow From Operations
Zoned Properties, Inc. (OTCQB: ZDPY) FY 2022 revenue was $2.66 million, an increase of 46% compared to $1.82 million in 2021.
FY 2022 Financial Highlights
Four Corners Property Trust Acquires Collision Property For $6.1M
Four Corners Property Trust Inc (NYSE:FCPT) has acquired a Caliber Collision property for $6.1 million. The property is located in a…